Clinical Trials Logo

Clinical Trial Summary

This is a prospective, open label pilot study in which patients with symptoms of acute or chronic pouchitis will receive FMT therapy delivered via pouchoscopy. The investigators hypothesize that FMT is a safe and effective treatment for patients with pouchitis. Our aims our:

1. To determine if symptoms of pouchitis can be successfully treated by Fecal Microbial Transplantation.

2. To determine if endoscopic appearance of ileal pouch improves following treatment by Fecal Microbial Transplantation.


Clinical Trial Description

This is a prospective, open label pilot study in which patients with symptoms of acute or chronic pouchitis will receive FMT therapy delivered via pouchoscopy.

Number of Subjects:

This study will aim to enroll approximately 30 patients with pouchitis.

Eligibility Criteria for FMT Group:

Both acute and chronic pouchitis will be eligible for treatment with FMT. Patients eligible for FMT will include:

1. Patients with history of proctocolectomy with Ileal Pouch-Anal Anastomosis (IPAA) (with pouchitis confirmed by endoscopy and pathology.

2. Concurrent therapies with mesalamine, immunomodulators, corticosteroids and biologic agents will be allowed to continue during study.

All patients who have a pouch for Inflammatory Bowel Disease (IBD) will be evaluated in Gastroenterology clinic or Colorectal surgery clinic. Patients who are eligible for the study will be identified during these regularly scheduled clinic visits. Patients who express interest will be set up for a meeting with a clinical research coordinator who will go over the study in detail and will obtain informed consent.

Prior to the FMT procedure stool samples will be checked for ova and parasites, C. difficile toxin and fecal calprotectin. Serum tests will include erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Anti-nuclear antibodies (ANA), complete blood cell count, HIV, screening for Hepatitis A, B, C (hep A IgM, hep B surface antigen and antibody, Hep C antibody), and creatinine. Eight days before treatment, patients will take a 5 day course of rifaximin that is discontinued 3 days before FMT treatment.

All patients with clinical suspicion for pouchitis will undergo pouchoscopy. Pouchoscopy (endoscopic evaluation of the pouch) is considered part of standard of care for management of these patients. All participants will undergo a pouchoscopy and this will not be considered a study procedure. This will be done in the endoscopic units at Mt. Zion, Parnassus and/or Mission Bay. During this procedure, for patients in the FMT group, the fecal transplant will take place. For FMT, 250 cc of FMT material (previously screened stool from OpenBiome) will be administered via the endoscope. During each FMT procedure 3 pouch biopsies will be collected. The scope will then be withdrawn and the patient will recover in the endoscopy unit as per protocol.

All patients who have undergone FMT for pouchitis will be called the next day to ensure no adverse events have occurred. A second FMT treatment and a follow up visit will be scheduled 4 weeks after the initial procedure. A pouchoscopy with 3 pouch biopsies will be conducted 6 six months after the initial FMT treatment to check for healing.

One week after the second FMT treatment, patients will be given the option to enroll in a 6 week, once per week FMT capsule therapy to be administered at a 1 hour clinic visit. Patients who receive capsules will be called the following to to ensure no adverse events have occurred.

Study participants will be asked to submit a stool sample prior to treatment, one month after treatment and then after that every three months after treatment up to 1 year in duration for a total of 6 samples. Additionally, blood serum samples will be collected at baseline and again 1 and 6 months after FMT procedure. Study participants will also be administered a patient survey to assess their clinical outcomes/symptoms prior to treatment and again 1 month after receiving treatment. In addition, all patients will receive a phone call 24 hours, 1 week, 1 month and and then every 3 months for 3 years after FMT treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02428361
Study type Interventional
Source University of California, San Francisco
Contact
Status Completed
Phase Early Phase 1
Start date May 28, 2015
Completion date March 4, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT04979832 - GM-CSF, Fosfomycin and Metronidazole for Pouchitis in Ulcerative Colitis Patients After Restorative IPAA Surgery Phase 1/Phase 2
Terminated NCT00061282 - Clotrimazole Enemas for Pouchitis in Children and Adults Phase 1/Phase 2
Not yet recruiting NCT05829109 - Fecal Microbiota Transplant for Patients With Chronic Pouchitis Early Phase 1
Recruiting NCT03136419 - Microbiota and Immune microEnvironment in Pouchitis N/A
Withdrawn NCT04640155 - Treating Chronic Pouchitis With a Low FODMAP Diet N/A
Completed NCT02201186 - To Determine the Effect of Honey Enema in the Treatment of Patients With Acute Pouchitis Phase 2
Completed NCT02790138 - A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis Phase 4
Not yet recruiting NCT01202396 - The Interaction Between Intestinal Microbiota, Innate Defense and Epithelial Integrity in the Development of Pouchitis N/A
Completed NCT03538366 - Fecal Microbiota Transplantation for Chronic Pouchitis N/A
Completed NCT04763564 - Efficacy of Liraglutide Therapy in Patients With IPAA Phase 2
Terminated NCT00583531 - Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis Phase 2
Recruiting NCT03524352 - the Prophylaxis of Recurrent Pouchitis After Fecal Microbiota Transplant in UC With Ileo-anal Anastomosis Phase 3
Completed NCT04820413 - Faecal Microbiota Transplantation From Normal Pouch Function Donor in the Treatment of Chronic Pouchitis N/A
Not yet recruiting NCT06443502 - A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis Phase 3
Recruiting NCT04089345 - Stelara fOr ChRonic AntibioTic rEfractory pouchitiS Phase 3
Not yet recruiting NCT03526796 - Hyperbaric Oxygen Therapy for Antibiotic Refractory Pouchitis N/A
Terminated NCT02782325 - Safety and Efficacy of Fecal Microbiome Transplantation (FMT) in the Treatment of Antibiotic Dependent Pouchitis (ADP) Phase 1/Phase 2
Completed NCT02828410 - Nutritional Impact of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With IPAA N/A
Recruiting NCT05578313 - Inflammatory Bowel Diseases (IBD) Cannabis Registry
Not yet recruiting NCT06316999 - Intestinal Ultrasound for the Evaluation of Pouchitis and Other Outcomes After Ileal Pouch-Anal Anastomosis N/A